Joshua Stein, MD
Urology · New Britain, CTNPI 1689842569
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Astellas Pharma US Inc at 32.8% of the total. Reporting peaked in 2019 at $19,018 and has fallen 97.2% since, to $524 in 2025. Among urology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $179.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$10K
- Pfizer$8K
- Johnson & Johnson$4K
- Janssen Scientific Affairs, LLC$3K
- Boston Scientific$933
- Ambu Inc.$850
- plus $4K from 25 others
Across 17 payments — averaging $1675.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Covidien LP$18K
- Medtronic$11K
What the payments were for
- Consulting fees$3,41011%
- Speaking & faculty fees$17,14058%
- Travel & lodging$4,34015%
- Food & beverage$4,49015%
- Education$3801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 32 | $9,758 |
| Pfizer | 21 | $7,899 |
| Johnson & Johnson | 9 | $4,064 |
| Janssen Scientific Affairs, LLC | 5 | $2,683 |
| Boston Scientific | 13 | $933 |
| Ambu Inc. | 1 | $850 |
| Coloplast | 18 | $590 |
| Verathon Inc. | 1 | $500 |
| Covidien LP | 8 | $494 |
| C. R. Bard, Inc. & Subsidiaries | 6 | $408 |
| Dendreon Pharmaceuticals LLC | 9 | $255 |
| Tolmar Pharmaceuticals, Inc. | 9 | $152 |
| Calyxo, Inc. | 1 | $137 |
| Procept Biorobotics Corporation | 1 | $133 |
| Medtronic | 4 | $122 |
| Bayer | 6 | $114 |
| Teleflex LLC | 1 | $113 |
| Antares Pharma, Inc. | 2 | $107 |
| Intuitive Surgical | 1 | $93 |
| Amgen | 3 | $59 |
| Photocure Inc | 1 | $44 |
| Rochester Medical Corporation | 1 | $43 |
| Aytu Biopharma, Inc. | 3 | $43 |
| Endo Pharmaceuticals Inc. | 2 | $36 |
| AbbVie | 2 | $34 |
| 180 Medical, Inc. | 1 | $21 |
| Therapeuticsmd, Inc. | 1 | $19 |
| Dentsply IH Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Hollister Incorporated | 1 | $14 |
| Metuchen Pharmaceuticals | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$16,861
- Erleada$6,507
- NPD Clinical Study$500
- Bard Urinary Drainage Bag$230
- Porges Coloplast$179
- CVAC Aspiration System$137
- AquaBeam Robotic System$133
- GreenLight XPS$125
- UroLift$113
- GENERAL KIDNEY STONE DISEASE$101
How this compares
$29,761 in reported general payments places this provider in the 95th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 189 | $173,471 |
| GemtesaVibegron | 45 | $38,514 |
| Mirabegron ErMirabegron | 28 | $23,855 |
| Tamsulosin Hcl | 1,092 | $15,796 |
| Finasteride | 992 | $11,733 |
| Solifenacin Succinate | 93 | $6,303 |
| Potassium Citrate ErPotassium Citrate | 50 | $6,095 |
| Silodosin | 71 | $5,915 |
| Oxybutynin Chloride ErOxybutynin Chloride | 176 | $4,228 |
| Testosterone | 30 | $3,515 |
| Dutasteride | 73 | $2,362 |
| Tolterodine Tartrate ErTolterodine Tartrate | 21 | $2,330 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 12 | $1,477 |
| Methenamine Hippurate | 19 | $1,011 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 51 | $926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $9,758 | $173,471189 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 urology providers in Connecticut.
Other urology in New Britain
- Paul CeplenskiNew Britain$4K
- Corlis Archer GoodeNew Britain$3K
- Daniel KellnerNew Haven$122K
- Gerard PregenzerEnfield$92K
- Mary SoysterTorrington$58K
- Preston SprenkleNew Haven$57K
- Grace BiggsDerby$52K
- Stanton HonigNew Haven$40K
- Steven ShichmanHartford$28K
- Christine LiawBridgeport$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.